close
1.

論文(リポジトリ)

論文(リポジトリ)
小山, 諭 ; 畠山, 勝義
出版情報: 新潟医学会雑誌 — 新潟医学会雑誌.  121  pp.622-625,  2007-11.  新潟医学会
本文リンク: http://hdl.handle.net/10191/32855
概要: The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor. Trastuzumab (Herceptin^[○!R]), a recombinant monoclonal antibody against HER2 has been becoming a key drug for HER2-overexpressed breast cancer, moreover to be used in ajuvant and neoadjuvant settings. 続きを見る
2.

論文(リポジトリ)

論文(リポジトリ)
小杉, 伸一
出版情報: 新潟医学会雑誌 — 新潟医学会雑誌.  130  pp.333-339,  2016-06.  新潟医学会
本文リンク: http://hdl.handle.net/10191/44816
概要: Surgery is still a mainstay of treatment for esophageal cancer; however, the 5-year overall survival of patients who underwent esophagectomy with 3-field lymphadenectomy is 40-50%, which implies the limilation of surgery as a local therapy. Since 1980s, the Japan Clinical Oncology Group) (JCOG) has conducted some multicenter randomized controlled trials to stablish a standard adjuvant therapy for this disease. Some representative JCOG studies and our relevant clinical studies are introduced and future perspectives are also discussed in this review. 続きを見る